.jpg?format=webp&width=780)
The study aims to assess the efficacy of immunotherapy in advanced HER2-mutated non-small cell lung cancer (NSCLC) and to compare the clinical and molecular features of patients with exon 20 insertion (ex20ins) and non-ex20ins. The study analyzed data from three cohorts and found that patients with non-ex20ins had potentially superior progression-free survival and overall survival under ICI-based therapy compared to ex20ins patients. The study suggests that ICI-based therapy may be an option for advanced HER2-mutated NSCLC, particularly in non-ex20ins patients. Further investigation is needed in clinical practice.
Like
Save
Share